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https://doi.org/10.1016/j.ccell.2018.03.003SUMMARYThe canine transmissible venereal tumor (CTVT) is a clonally transmissible cancer that regresses spontane-
ously or after treatment with vincristine, but we know little about the regression mechanisms. We performed
global transcriptional, methylation, and functional pathway analyses on serial biopsies of vincristine-treated
CTVTs and found that regression occurs in sequential steps; activation of the innate immune system and host
epithelial tissue remodeling followed by immune infiltration of the tumor, arrest in the cell cycle, and repair of
tissue damage. We identified CCL5 as a possible driver of CTVT regression. Changes in gene expression are
associated with methylation changes at specific intragenic sites. Our results underscore the critical role of
host innate immunity in triggering cancer regression.INTRODUCTION
The canine transmissible venereal tumor (CTVT) is a contagious
cancer allograft (Belov, 2012; Fassati and Mitchison, 2010;
Murchison, 2008). Remarkably, CTVT is able to evade host
immune-detection, allowing its worldwide spread in dogs (Belov,
2012; Murchison, 2008).
First described in the nineteenth century (Blaine, 1810; Novin-
ski, 1876), the tumor grows mostly on male and female external
genitalia and it is naturally transmitted between dogs by coitus,
biting, or licking tumor-affected areas (Murchison, 2008). CTVT
can be transplanted experimentally between dogs and even to
other members of the Canidae family (Cohen, 1985). The similar-
ity of the karyotype observed in CTVT samples from distant
geographical areas suggested that this tumor originated from a
common ancestor (Fujinaga et al., 1989; Idowu, 1977). A LINESignificance
There are three known clonally transmissible cancers in nature
clams. CTVT is the only one that regresses, spontaneously or a
cancer regression in general. By performing systematic genom
with vincristine induces host innate immune genes and epithe
Gene expression changes correlate with demethylation of spe
into the molecular and immunological mechanisms driving
whereby innate immunity plays a critical role in triggering canc
620 Cancer Cell 33, 620–633, April 9, 2018 ª 2018 The Author(s). Pub
This is an open access article under the CC BY license (http://creativeelement insertion into the MYC locus present in CTVTs but not
in the host dogs supported this notion (Katzir et al., 1985).
More recently, the clonal origin of CTVT was proven by analysis
of microsatellite polymorphisms, mtDNA, and by dog leukocyte
antigen (DLA) typing (Murgia et al., 2006; Rebbeck et al., 2009),
and confirmed by genome-wide sequencing (Murchison et al.,
2014). Together with the Tasmanian devil facial tumor disease
(Belov, 2012) and the recently described leukemia-like cancer
in soft-shell clams (Metzger et al., 2015, 2016), CTVT is a natu-
rally occurring transmissible cancer of clonal origin.
CTVT was the first tumor to be experimentally transplanted
before the era of inbred mice (Novinski, 1876). Experimentally
transplanted CTVT is clinically characterized by a progressive
(P), a stationary (S), and a regressive (R) phase (Epstein and Ben-
nett, 1974). In the P phase, there is rapid growth of the tumor
to become a pedunculated, cauliflower-like exudative mass.: CTVT, the Tasmanian devil facial disease, and leukemias of
fter vincristine administration, providing a unique model for
e-wide analysis of CTVT regression, we found that treatment
lial differentiation, triggering immune-rejection of the tumor.
cific intragenic regions. Our results provide a unique insight
cancer regression and support recently proposed models
er rejection.
lished by Elsevier Inc.
commons.org/licenses/by/4.0/).
Table 1. Histopathology on Tissue Sections of CTVT-5 and CTVT-6
CTVT Sample, Day
(Biopsy Number) Sex of Dog CTVT Phase Mitosis/1.000 Cells Lymphocytes (%) Granulocytes (%)
Apoptotic/Necrotic
Cells (%)
5, day 0 (biopsy 1) male P 2.4 3.40 2.70 0
5, day 6 (biopsy 2) S/R 0 15.60 NA 16.30
5, day 14 (biopsy 3) R 0 NA NA 80
6, day 0 (biopsy 1) female P 4.7 0 8.86 0
6, day 6 (biopsy 2) P/S 0 1 0 20
6, day 14 (biopsy 3) S 0 1 0 20
17a day 0 (biopsy 1) male P NAb NA NA NA
17a day 22 (biopsy 2) S NA NA NA NA
17a day 48 (biopsy 3) S/R NA NA NA NA
aCTVT-17 could not be analyzed due to poor tissue preservation.
bNA, not available.
See also Figure S1.Microscopically there is abundance of mitotic cancer cells and
few infiltrating lymphocytes. In the S phase, growth slows
considerably; there are fewer cancer cells in mitosis, and more
apoptotic cells and infiltrating lymphocytes. In the R phase, there
are abundant infiltrating lymphocytes, cancer cells disappear,
the tumor stroma collapses, and there is collagen deposition
(Chu et al., 2001; Mukaratirwa et al., 2004). Recovered dogs
are immune to re-inoculation (Cohen, 1985). In naturally occur-
ring CTVT, spontaneous regression is also observed, albeit
less frequently than in transplanted CTVT (Perez et al., 1998).
However, natural CTVT is often sensitive to radiotherapy and
chemotherapy and even a single treatment may induce regres-
sion (Gonzalez et al., 2000; Thrall, 1982).
Histology of tumors in the P and R phases indicated that
regression is characterized by apoptosis of cancer cells and
the presence of tumor-infiltrating lymphocytes (TILs) (Gonzalez
et al., 2000; Perez et al., 1998) with production of anti-tumor
immunoglobulin Gs (Epstein and Bennett, 1974). Thus complete
regression seems to depend on an appropriate immune
response, a notion supported by the fact that immunosup-
pressed dogs and puppies develop more aggressive CTVT
that lacks TILs and is rarely eliminated (Yang and Jones, 1973).
It is not clear how CTVT evades immune-detection during
transmission and growth but triggers rejection in the R phase.
In transplanted CTVT, a model has been proposed whereby
secretion of transforming growth factor b (TGF-b) by cancer cells
suppresses class I and II DLA expression and NK (natural killer)
cell activity. TGF-b is counteracted by interleukin-6 (IL-6), pro-
duced by TILs, hence, when a critical threshold is reached,
TGF-b is overcome by IL-6, resulting in re-expression of DLAs
on CTVT cells and their rapid elimination (Chiang et al., 2013;
Hsiao et al., 2004). There is little evidence, however, that this
mechanism operates in natural CTVT.
Although the natural spread of CTVT is confined to dogs,
humans and dogs share many forms of cancer with similar clin-
ical presentation, pathology, and genetic mutations, including
osteosarcoma, soft tissue sarcoma, non-Hodgkin lymphomas,
and melanoma (Schiffman and Breen, 2015). This suggests
that understanding regression of CTVT could be important in
identifying potential mechanisms of regression in human can-
cers. To understand the process leading to CTVT regression,we analyzed biopsies from natural CTVTs collected before and
after treatment with vincristine and contrasted cases that fully
regressed to cases that did not regress.
RESULTS
We collected three serial biopsies from two naturally occurring
tumors, one in a male (CTVT-5) and one in a female (CTVT-6)
mixed breed dog (Table 1). The dogs were treated with a single
intravenous administration of 0.025 mg/kg vincristine. The first
biopsy was collected pre-therapy; the second and third biopsies
were collected 6 and 14 days post-therapy, respectively. Macro-
scopically, both pre-therapy CTVTs were large (>3 cm diameter),
cauliflower-like, ulcerated, and bleeding (Figure S1). Both CTVTs
responded to vincristine, becoming smaller with reduced
bleeding. However, at the time of the third biopsy, CTVT-5 had
almost completely regressed, whereas CTVT-6 still presented
a significant tumor mass (Figure S1). Biopsies were examined
microscopically to count mitotic figures, TILs, granulocytes,
and apoptotic cells (Table 1). The most striking difference
between the two samples was the lack of TILs in CTVT-6,
whereas in CTVT-5 TILs represented 3.4% of total cell count in
the first biopsy and 15.6% in the second biopsy. Both samples
contained 15%–20% of apoptotic cells in the second biopsy,
increasing to >80% in CTVT-5 but remaining stable in CTVT-6.
Based on the macroscopic appearance and the histology, we
classified the CTVT-5 serial biopsies as P, S, and R phases
and the CTVT-6 biopsies as P, P/S, and S, respectively. A third
case in a male mixed breed dog (CTVT-17) (Table 1; Figure S1)
presented at a different clinic after the first two cases and a
biopsy was collected at day 0, and days 22 and 48 post-vincris-
tine. Clinical examination indicated that the biopsy taken at day
22 was S phase and biopsy taken at day 48 was R phase. Poorer
tissue preservation prevented pathological analysis of CTVT-17.
RNA-Seq Identifies Genes Differentially Regulated in
S and R Phases
To gain a deeper understanding of the mechanisms of CTVT
regression, we sought to identify specific genes and pathways
that are differentially expressed in the serial biopsies. We
reasoned that genes driving regression would be differentiallyCancer Cell 33, 620–633, April 9, 2018 621
Figure 1. Diagram of the Experimental Pipeline Used to Study CTVT
Regressionregulated in P versus S or R phase. We also sought to determine
if epigenetic regulation of gene expression might be important.
Therefore, we performed transcriptome and methylome ana-
lyses in parallel to match differentially regulated and differentially
methylated genes and conducted gene pathway analysis to
identify key host-CTVT interactions. CTVT-6 provided an impor-
tant control because it did not regress. Our approach is summa-
rized in Figure 1.
Nucleic acids were extracted from biopsies and total RNAwas
prepared for sequencing following the Illumina TruSeq mRNA
protocol and sequenced on an Illumina NextSeq to yield an
average of 15 million reads per sample. RNA extracted from
CTVT-17 did not pass quality control and could not be
sequenced. Following alignment and removal of PCR duplicates,
we applied rigorous generalized linear models for all of the differ-
ential gene expression analyses, modeling count data using the
negative binomial distribution via the BioConductor library
DESeq and using a matrix (regression status, CTVT, time point
before and after treatment), which allows to incorporate paired
data into multifactorial analysis (Anders and Huber, 2010;
Gentleman et al., 2004) (Table S1). We compared changes in
gene expression occurring in each sequential biopsy; a total of
6,756 genes were found differentially regulated (2-fold or
more). To better capture changes likely to be of biological signif-
icance, we applied two stringent cutoffs, requiring a fold-change
(FC) > 10 and an adjusted p value (adj-p) < 0.01 (Benjamini-
Hochberg test). Using this filter, we detected 1,016 differentially
expressed genes, of which 704were upregulated and 312 down-
regulated (Table S1).
Expression analysis (Figure 2A; Table S2) revealed that some
genes were already upregulated in the second biopsy, while
others were upregulated in the third biopsy. For CTVT-6, both
the first and second biopsies were more similar to the P phase
of CTVT-5 than to the S phase, whereas the third biopsy was622 Cancer Cell 33, 620–633, April 9, 2018more similar to the S phase of CTVT-5 (Figure 2A). Downregu-
lated genes progressively faded in CTVT-5 but not in CTVT-6
(Figure 2A). These findings agreedwith the lack of clinical regres-
sion and the pathology of CTVT-6 (Table 1; Figure S1).
To confirm and extend the RNA sequencing (RNA-seq) results,
we investigated six additional CTVT cases (CTVT-7xx) acquired
by natural transmission, three of which regressed (CTVT-765,
-766, and -772) and three of which did not (CTVT-761, -774,
and -775) following treatment with vincristine. Due to ethical
and practical constraints, biopsies from these CTVTs were
collected before treatment (biopsy 1 or B1) and at day 28 after
vincristine (biopsy 2 or B2); hence they did not have the same
temporal resolution of CTVT-5 and CTVT-6. Nonetheless, these
samples were collected years apart from CTVT-5 and CTVT-6,
on a different continent and were sequenced in a different labo-
ratory, and thus can be considered as a completely independent
experiment to validate key results.
To confirm the clinical observations, DNA from these 7xx
CTVTs was analyzed by qPCR to measure the LINE-Myc inser-
tion, a hallmark of this tumor (Katzir et al., 1985), as well as a
region of MHC class II DLA DQA-1 shared between CTVT and
host and a region of DLA DQA-1 specific for CTVT (Murgia
et al., 2006). CTVT-765, -766, and -772 regressed clinically and
showed loss of LINE-Myc DNA and tumor-specific DLA
DQA-1. In contrast, CTVT-761 and -774 did not regress clinically
and maintained LINE-Myc and tumor-specific DLA DQA-1 (Fig-
ure 2B). CTVT-775 also did not regress clinically but showed
some loss of LINE-Myc and tumor-specific DLA DQA-1
(Figure 2B).
RNA from these samples was sequenced to yield between 18
and 31.5 million reads per sample, except B 1 of CTVT-774,
which did not pass quality controls and was not included in the
subsequent analysis. Principal-component analysis revealed a
clear separation between B1 and B2 of the 7xx regressing
tumors but not for the biopsies of non-regressing CTVTs (Figures
S2A and S2B). To examine the overall reproducibility of the ex-
periments, we compared log2FC in gene expression in B3/B1
of CTVT-5 with the mean log2FC in B2/B1 of the regressive or
non-regressive 7xx CTVTs. Considering all expressed genes,
correlation (Pearson’s coefficient) was 0.80 for the regressive
CTVTs (Figures S2C and S2D), rising to 0.94 when considering
only those genes that passed the FC > 10 adj-p < 0.01 cutoff,
indicating high reproducibility.
In the regressive 7xx CTVTs, 1,350 genes were differentially
regulated in B2 relative to B1 (FC > 10 and adj-p < 0.01), but
only 59 genesmet these cutoffs in the non-regressive 7xx CTVTs
(Table S1). Expression analysis of these 1,350 genes revealed a
pattern of expression changes similar to CTVT-5 and CTVT-6,
which discriminated between regressing and non-regressing
tumors (Figure 2C). The overlap between significantly changed
genes in CTVT-5 (B3/B1) and in the regressive 7xx CTVTs
(B2/B1) was 63.7% (648/1,016 genes) (Figure 2D). Further anal-
ysis of the 1,350 genes significantly changed in the regressive
7xx CTVTs identified 189 genes that were also statistically signif-
icantly different (p < 0.05) when comparing changes in their
expression levels (B2/B1) in regressive versus non-regressive
7xx CTVTs (regressive [R]-B2/R-B1 versus non-regressive
[NR]-B2/NR-B1) (Figure 2C, red lines on the right; Table S2). Of
these 189 genes, 127 genes were also differentially expressed
Figure 2. Transcriptional Profiling Detects a
Signature of CTVT Regression
(A) Heatmap showing differential expression of the
1,016 significant genes (FC > 10 and adj-p < 0.01)
relative to the geometric mean of CTVT-5 B1 and
CTVT-6 B1 (mean of the logs). Genes are sorted by
expression of B3/geometric mean of (CTVT-5 B1,
CTVT-6 B1). B1, first biopsy; B2, second biopsy;
B3, third biopsy.
(B) qPCR on DNA extracted from biopsies
obtained before (B1, day 0) and after (B2, day 28)
vincristine administration of the 7xx CTVTs. Spe-
cific primers were used to amplify LINE-MYC DNA
(tumor specific), DLA DQA-1 (tumor specific), and
DLA DQA-1 (common to both host and tumor). All
quantifications are relative to b-actin.
(C) Heatmap showing differential expression of the
1,350 significant genes in the 7xx CTVTs (FC > 10
and adj-p < 0.01) relative to the geometric mean of
the five B1 samples. Genes are sorted by
expression of B2/geometric mean of 7xx B1s.
Each row represents an individual gene. RNA-seq
data were not available for CTVT-774 B1. The red
lines next to each row indicate genes that reached
statistical significance in the R-B2/R-B1 versus
NR-B2/NR-B1 comparison.
(D) Venn diagram showing the degree of overlap
between CTVT-5 R versus P genes (1,016 genes),
the 7xx CTVTs B2 versus B1 genes (1,350 genes)
and genes that reached statistical significance in
the R-B2/R-B1 versus NR-B2/NR-B1 comparison
(189 genes).
See also Figure S2 and Tables S1 and S2.(FC > 10 adj-p < 0.01) in CTVT-5 but not in CTVT-6, thus forming
a potential ‘‘core’’ signature of regression: they reproduce
across experiments and are statistically significantly different
between regressing and non-regressing tumors within the sec-
ond experiment (Figure 2D; Table S2). Overall, these data indi-
cated the existence of a signature of regression, which we
sought to explore in greater depth.
Inflammation and Epithelial Cell Proliferation
Characterize the Early Response to Vincristine
The CTVT-5 expression analysis revealed dynamic changes in
gene expression and we hypothesized that this may reflect
sequential steps ultimately leading to CTVT regression. We
therefore examined the temporal nature of the changes in
gene expression (Figure 3A). We classified genes into several
groups based on when they reached an FC > 10 (at the adj-
p < 0.01 cutoff): we found 150 ‘‘early up’’ genes (upregulated
[>10-fold] in S phase relative to P phase), 203 ‘‘late up’’ or
‘‘late down’’ genes (up- or downregulated [>10-fold] in R relative
to S, but not in S relative to P), and 663 ‘‘progressive’’ genes
(progressively up- or downregulated [>10-fold] in R relative
to P, but not in R relative to S, or S relative to P) (Figures 3A
and 3B).Differentially expressed genes corre-
sponding to these three different tempo-
ral profiles were studied in each CTVT
for pathway enrichment using IngenuityPathway Analysis (IPA) (www.qiagen.com/ingenuity) (Figures
3C–3E). Individual IPA profiles were compared based on statis-
tical significance (Fisher’s exact test) and similarity (Figure 3C;
Table S3). In CTVT-5, the top early networks were related to
recruitment of, and invasion by, granulocytes, agranulocytes,
and leukocytes, formation and inflammation of skin, as well as
a broader ‘‘cancer’’ signature. This was followed by proliferation
and activation of lymphocytes, NK cells, and B cells. The late
stage was characterized by upregulation of networks related to
migration and invasion of cells in general, proliferation of con-
nective tissue, and migration of vascular endothelial cells sug-
gesting formation of new tissue (Figures 3C–3E; Table S3). These
pathways were shared between CTVT-5 and the regressive 7xx
CTVTs (Figures 3C–3E; Table S3).
IPA showed an enrichment within the early up gene group for
genes involved in skin inflammation, epithelial cell differentiation
and development, and cell migration (p < 0.01, Fisher’s exact
test) (Table S3). Key genes in these early networks that were
also differentially expressed in the regressive 7xx CTVTs
(FC > 10 and adj-p < 0.01; Tables S1 and S2) included TP63,
which is required for epithelial and keratinocyte differentiation
(Crum and McKeon, 2010; Stramer and Martin, 2005), as well
as keratins such as KRT4 (FC = 92) and KRT15 (FC = 104), whichCancer Cell 33, 620–633, April 9, 2018 623
Figure 3. Dynamic Changes in Gene
Expression across Sequential Biopsies
Identify Pathological Processes during
CTVT Regression
(A) Schematic depiction of the changes in
expression for the early, progressive, and late
genes in the different CTVT phases. The dotted
line indicates an expression FC > 10 relative to
baseline values in the P phase.
(B) Venn diagram illustrating the overlap between
differentially expressed genes across all three
comparisons. The diagram explains how differ-
entially expressed genes were classified into three
categories: early, late, and progressive.
(C) Pie charts indicating the relative proportion of
IPA gene networks within the early, progressive,
and late upregulated gene groups of CTVT-5 and
their relative proportion within the regressing 7xx
CTVTs.
(D and E) Heatmaps of comparative IPA analyses
showing the top 30 diseases and biofunction
pathways (ex cancer) (D) or canonical pathways
(E) for B1, B2, and B3 of CTVT-5 and each indi-
vidual regressive 7xx CTVTs. Pathways are clus-
tered based on significance (log10 p value,
Fisher’s exact test) and similarity.
See also Table S3.are expressed in the basal layer of stratified epithelia (Moll et al.,
2008) (Figure 4A). Overall, within this group, the overlap between
CTVT-5 and the regressing 7xx CTVTs was 78% (42/54 genes)
(Table S4). There was a prominent skin inflammatory component
in the network, classified by IPA as psoriasis and Netherton syn-
drome, a disease characterized by chronic inflammation and
dermal infiltrate of eosinophils and neutrophils (Leclerc-Mercier
et al., 2016) (Figure 4A). Key early up genes involved in inflamma-
tion included S100A8 (FC = 18) and S100A9 (FC = 14), which are
endogenous TLR4 ligands (Vogl et al., 2007), PIGR (FC = 560),
which mediates transport of IgA across mucosal epithelial cells
(Kaetzel, 2005), as well as the chemotactic cytokine CCL5
(FC = 11) (Figure 4A; Table S1).
To identify possible early drivers of regression, we plotted
normalized RNA reads of early up genes of CTVT-5, which
regressed, versus CTVT-6, which did not regress. CCL5 was
among the most prominent outliers (Figure 4B). CCL5/RANTES
is a key chemokine, which, by binding to its receptor CCR5,
promotes chemotaxis of monocytes, T lymphocytes, NK cells,624 Cancer Cell 33, 620–633, April 9, 2018eosinophils, and basophils, and can be
produced by epithelial cells and keratino-
cytes (Li et al., 1996; Proost et al., 1996).
CCL28 (FC = 30 in CTVT-5 and 3 in CTVT-
6) was another prominent outlier (Fig-
ure 4C; Table S1). These chemokine
genes also reached higher expression
levels in the regressive relative to the
non-regressive 7xx CTVTs and high
absolute levels (Figure 4D). The relative
change in CCL5 expression was signifi-
cantly different between regressive
and non-regressive CTVTs (R-B2/R-B1versus NR-B2/NR-B1, p < 0.01), whereasCCL28 reached statis-
tical significance in the regressive CTVTs only (Figure 4D). CCR5
signaling was among the most significant canonical pathways
identified by IPA in the regressive 7xx CTVTs (Figure 3E; Table
S3). Furthermore, CCL5 was one of four early up genes in the
core signature of regression, the others being CD8, MFAP4,
which also promotes monocytes chemotaxis (Schlosser et al.,
2016), and UBASH3A, a member of the T cell ubiquitin ligand
family (Table S2). Thus CCL5 might be important to trigger
rejection.
Immune Cell Infiltration, Cell-Cycle Arrest, and Tissue
Remodeling Characterize the Secondary Response to
Vincristine
Next we focused on the prominent immunological network
detected by IPA in all the regressive CTVTs. A group of 88 immu-
nological genes was significantly upregulated in CTVT-5, but not
in CTVT-6, with a good overlap of individual genes between
CTVT-5 and the regressive 7xx CTVTs (z60% overlap at
Figure 4. Early Upregulation of Epithelial and Inflammation-Related Genes Characterizes CTVT Regression
(A) IPA diagram showing gene networks of early upregulated genes in CTVT-5. Inflammation-related nodes are highlighted in red. (B) Scatterplot illustrating
correlation between normalized RNA-seq counts for early upregulated genes in CTVT-5 (B2) and CTVT-6 (B3). Best-fit line is shown in red.
(C and D) Gene expression levels of CCL5 and CCL28 in CTVT-5 and CTVT-6 (C), and in the additional 7xx CTVT samples (D) (mean ± SEM, n = 3). Significant
adj-p values are shown (****p < 0.0001, ***p < 0.001, **p < 0.01): all have FC > 10.
See also Table S4.
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Figure 5. Upregulation of T, NK, and B Cell-Related Genes Characterizes the Secondary Response to Vincristine
(A) Expression changes in B1, B2, or B3 of 88 progressive immunological genes in CTVT-5 and CTVT-6.
(B) Diagram showing 10 representative nodes obtained by IPA using the 88 progressive immunological genes upregulated in CTVT-5. Key nodes are shown in
blue; key genes belonging to the core signature of regression are shown in red; progressive up genes in common between CTVT-5 and the regressive 7xx CTVTs
are shown in purple.
(C) The 88 immunological genes were annotated manually using Genecards and the available literature into four groups: I, inflammation/innate immunity; T,
T cells; NK, natural killer cells; and B, B cells. Fold upregulation of genes in the S and R phase is relative to the P phase and is based on the normalized RNA-
seq reads.
See also Tables S4, S5, and S6.FCR 10 and adj-p < 0.01) but a 0% overlap with the non-regres-
sive CTVTs at the same cutoff (Figure 5A; Table S4). These genes
formed networks, which included CCR5 signaling, leukocyte
extravasation, and T, NK, and B cell function (Figure 5B;
Table S3).626 Cancer Cell 33, 620–633, April 9, 2018We classified these immunological genes into four groups
based on the existing literature and available experimental evi-
dence: genes involved in inflammation, T cell function, NK cell
function, and B cell quantity or function (Figure 5C; Table S4).
Inflammation-related genes were the most upregulated in the
S phase and were further upregulated in the R phase. T cell- and
NK cell-related genes were progressively upregulated. B cell
genes, albeit less prominent in quantity and expression levels,
were also progressively upregulated (Figure 5C), in agreement
with pathological studies reporting infiltration of CTVT by B cells
(Perez et al., 1998) and the presence of a B cell signature in acute
allograft rejection (Sarwal et al., 2003).
To further validate key pathways, we performed IPA using the
189 genes that reached statistical significance in the R-B2/R-B1
versus NR-B2/NR/B1 comparison for the 7xx CTVTs or the 127
genes forming the core regressive signature (Figure 2D; Table
S2). We compared these IPAs with those obtained with each
regressive CTVT. This analysis confirmed that granulocyte/
agranulocyte adhesion and diapedesis, communication be-
tween innate and adaptive immunity, T cell signaling, and
CCR5 signaling were the most significant upregulated pathways
across all datasets (Table S5).
To better understand the contribution of the host and the
tumor to the changes in gene expression, we took advantage
of several sources of information regarding tissue origin. Firstly,
deep sequencing of the CTVT genome revealed that 657 genes
were deleted or had a premature stop codon in CTVT (Murchison
et al., 2014) (Table S1), hence they could be used as markers of
host tissue. Secondly, the CTVT genome has accumulated over
two million mutations (Murchison et al., 2014), which we could
use to map a particular gene to host or CTVT, provided that
the sequencing depth was sufficient and that at least two muta-
tions were present within a particular transcript. Using this filter,
we sampled 63 upregulated genes that passed the FC > 10
adj-p < 0.01 cutoff in CTVT-5 and were also involved in key
IPA networks, including skin inflammation. The analysis showed
that almost all of them were of host origin (Table S6), indicating
that the host stroma contributes to CTVT regression.
We found no early downregulated genes and instead found
177 progressive genes downregulated in CTVT-5 relative to
CTVT-6. The main functional networks affected were cell cycle,
DNA replication and recombination, and organ development
(Figure 6A; Table S3). The large cell-cycle network included
many genes involved in the formation of the mitotic spindle,
condensation, and segregation of chromosomes (Figures S3A
and S3B; Table S7). This is consistent with the inhibitory effect
of vincristine on microtubule dynamics, leading to perturbation
of the mitotic spindle and cell-cycle arrest (Ngan et al., 2001).
These genes remained unchanged in CTVT-6, confirming the
specificity of the effect (Figure S3A; Table S7). Notably, the
cell-cycle gene network was not detected in the regressive 7xx
CTVTs (Figure 6A; Table S3), suggesting that the dramatic
changes in cell cycle occurred early and were missed in the sec-
ond biopsy of the regressive 7xx CTVTs, which was collected
28 days after vincristine treatment.
Pathway Analysis on Genes that Cease to Be Expressed
duringRegression Suggests that CTVTMayBeSimilar to
Melanoma
The late downregulated geneswere only detected in CTVT-5 and
not in CTVT-6, suggesting that they were closely linked to
advanced tumor regression (Table S1). The third biopsy of
CTVT-5, collected at 14 days after vincristine administration,
contained 80% necrotic or apoptotic cells (Table 1). We tookadvantage of this fact to investigate the possible cell or tissue
of origin of CTVT. We reasoned that genes that disappeared in
the last biopsy were more likely to belong to CTVT (except for
immunological genes), and hence could be used to obtain a tran-
scriptional profile of the tumor itself. There were 135 genes
downregulated in the late stage. The IPA functional networks
with the higher confidence were related to solid cancers (Fig-
ure 6B), and within these groups melanoma had the highest con-
fidence and a large number of genes (80 genes, p = 1.223 108)
(Figures 6B and S4; Table S3). Remarkably, IPA of downregu-
lated genes in the regressive 7xx CTVTs also showed that the
functional networks with the highest confidence and greatest
number of genes were skin cancer and cutaneous melanoma
(>180 genes, p < 1.5217) (Figure 6B; Table S3). The top three
IPA disease pathways identified across all CTVTs were skin
cancer, cutaneous melanoma, and melanoma (Figure 6C).
Furthermore, skin cancer and cutaneous melanoma emerged
as the most significant downregulated disease and biofunctions
pathways within the core signature of 127 genes and across all
datasets (Table S8).
Although the highly significant cancer signature was ex-
pected, the melanoma signature was not, given that CTVT
has been proposed have a histiocytic origin (Cohen, 1985; Mo-
zos et al., 1996). The histological classification of CTVT was
mainly based on positive immunostaining for lysozyme (en-
coded by LYZ), a1-antitrypsin (encoded by SERPINA1), and
vimentin (encoded by VIM) in about 30%–50% of the tumor
cells (Mozos et al., 1996). However, our RNA-seq analysis
(Table S1) showed no significant change in the expression
levels of LYZ (Ensembl ID: ENSCAFG00000000426), SERPINA1
(Ensembl ID: ENSCAFG00000017646), or VIM (Ensembl ID:
ENSCAFG00000004529) in any regressing CTVTs, hence it is
unlikely that such markers are specific for the tumor, although
we note that histamine biogenesis was a prominent canonical
pathway (Figure 6D).
To explore this issue further, we assessed the relative enrich-
ment of our late downregulated gene signature in the human
NCI-60 cancer cell line panel originating from other solid tumors
(Pfister et al., 2009). We found that melanoma was among the
most enriched tumor cell types, and that this showed the most
significant difference when compared with all other solid tumors
in the panel (Figures S4B and S4C). Thus we concluded that
CTVT has similarities to melanoma at the transcriptional level.
DNA Methylation Changes during CTVT Regression
Next we investigated whether changes in gene expression were
associated with epigenetic modifications. DNA methylation at
CpG islands in promoters often causes silencing of genes and,
conversely, their demethylation stimulates gene expression
(Bird, 1986; Esteller, 2005). However, it was also shown that
methylation occurs in other DNA regions, such as CpG island
shores within 2 kb of transcriptional start site and even within
exons near the 30 end of genes (Hovestadt et al., 2014; Li
et al., 2010). Methylation of such regions appears to impact on
gene expression more strongly than CpG island methylation
(Hovestadt et al., 2014). Therefore, we conducted a global
methylation analysis using MeDIP-seq (Taiwo et al., 2012) on
the sequential biopsies of CTVT-5, CTVT-6, and CTVT-17, and
mapped methylation levels within the promoter, the first exon,Cancer Cell 33, 620–633, April 9, 2018 627
Figure 6. Downregulated Genes Show a Melanoma-like Signature
(A) Pie charts indicating the relative proportion of each functional IPA network within the progressive and late downregulated gene groups of CTVT-5 and within
the downregulated gene groups of the regressing 7xx CTVTs. Note that no early downregulated gene was detected in CTVT-5.
(B) Plots showing the confidence value of the main functionally annotated pathways identified by IPA for the late downregulated gene group in each regressing
CTVT. The p value (Fisher’s exact test) for each pathway is shown on the x axis.
(C and D) Heatmaps of comparative IPA analyses showing the top 10 diseases and biofunction pathways (C) or canonical pathways (D) for each individual
regressive CTVTs. Pathways are clustered based on significance (Fisher’s exact test) and similarity.
See also Tables S7 and S8; Figures S3 and S4.
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Figure 7. Changes in Gene Expression
Correlate with Specific Changes in DNA
Methylation
Demethylation profiles of early (A), progressive (B),
and late (C) upregulated genes across serial
biopsies of CTVT-17 (red), CTVT-5 (yellow), and
CTVT-6 (green). Demethylation scores were
obtained for individual genes by quantifying de-
methylation levels within specific regions of genes
(%2 kb upstream of first exon; first exon; first
intron; internal exons; internal introns; last exon;
%2 kb downstream of last exon) and normalized
by subtracting the corresponding demethylation
values observed for non-expressed genes. Box-
plots illustrate the variation within these values
across each gene-list (boxes extend to the first
and third quartile, whiskers extend to 1.53 inter-
quartile range, and the line represents median
values). For each CTVT sample, boxplots are in
order (from left to right): first, second and third
biopsy.
See also Figure S5.the first intron, internal exons, internal introns, the last exon, and
the 30 end of genes. We thenmatched themethylation pattern for
each gene with our transcriptional data (RNA-seq) to correlate
methylation levels and location to gene expression. We main-
tained the same overall classification based on when genes
were up- or downregulated (early, progressive, and late). To
detect specific changes, we normalized the signal by subtracting
themethylation values of genes that were not expressed in any of
the biopsies. Although we were unable to perform transcriptional
analysis on CTVT-17, we observed consistent methylation
profiles across all biopsies for each gene list obtained from
RNA-seq of CTVT-5 and CTVT-6 (Figures 7, S5A, and S5B).
In the early upregulated genes we observed demethylation at
the first exon across all CTVT samples. This demethylation
pattern was sustained in CTVT-5 and CTVT-17, but was reduced
in the third biopsy of CTVT-6 (Figure 7A). A more complex deme-
thylation pattern was observed in the late upregulated genes.
Here internal exons and the last exon showed either progressive
or sustained demethylation, from the first to the last biopsy. The
exception was CTVT-6, whose demethylation levels dropped inthe third biopsy. Demethylation was
weaker in the progressive upregulated
genes, presumably because the over-
represented immunological genes did
not change their methylation patterns
(Figure 7B).
Hypermethylation was found in down-
regulated genes. This was more pro-
nounced for the progressive downregu-
lated genes (Figure S5). In CTVT-5 and
CTVT-17, the internal and last exons
showed progressive hypermethylation.
In CTVT-6, the internal exon showed no
progressive change in methylation,
whereas the last exon showed hyperme-
thylation in the first and second biopsies,
which was fainter in the third biopsy(Figure S5). Thus CTVT-6 may be initially epigenetically permis-
sive for changes in gene expression important for regression
but this condition is not stable. These results support the hypoth-
esis that epigenetic changes play a significant role in vincristine-
induced regression of CTVT. Because most upregulated genes
were of host origin, it seems likely that epigenetic changes in
stroma and host tissue surrounding the tumor were critical to
induce regression.
DISCUSSION
CTVT is unique among naturally transmissible cancers
because it can regress (Cohen, 1985; Fassati and Mitchison,
2010). Although spontaneous regression is uncommon, a sin-
gle dose of vincristine or radiation is often sufficient to cure
this cancer in a few weeks (Gonzalez et al., 2000). This sug-
gests that CTVT is particularly susceptible to changes that
break tolerance to this cancer; however, a comprehensive
analysis of the events leading to regression of natural CTVT
was lacking.Cancer Cell 33, 620–633, April 9, 2018 629
To this end we compared tumors that regressed with tumors
that did not regress to investigate mechanisms of CTVT regres-
sion by transcriptional and methylation profiling. We observed
that differential expression of many genes occurred in parallel
with changes in the pathology, revealing a stepwise process
that begins with a strong inflammatory response and epithelial
and keratinocyte proliferation, followed by immune infiltration
of T, NK, and B cells, and arrest in the cell cycle. Ultimately, in
regressing CTVT, there is loss of tumor cells, cell migration,
and tissue remodeling. This process has similarities with wound
healing (Strbo et al., 2014), as Mukaratirwa et al. (2004) noted in
their histochemical study of CTVT.
The early phase was characterized by a strong and reproduc-
ible upregulation of genes involved in epithelial cell and keratino-
cyte differentiation, including many keratins (KRT4 KRT13,
KRT15, KRT23, KRT78, and KRT80) and epithelia-specific tran-
scription factors such as TP63 (Mehrazarin et al., 2015; Pellegrini
et al., 2001). This suggested that mucosal and/or skin remodel-
ing is one of the first responses characterizing the transition from
the P to S phase CTVT. Since keratins were mostly of host origin,
we propose that proliferation of keratinocytes and epithelial stem
cells of the basal layer is an attempt by the surrounding tissue to
contain or replace the malignant tissue. However, these genes
were not found in the core signature of regression, suggesting
that epithelial cell and keratinocyte differentiation is necessary
but not sufficient to trigger regression and may also be associ-
ated with the S phase.
Within the early upregulated genes, we detected a significant
number of genes involved in inflammation. Expression of genes
involved in interferon signaling (IRF7, ISG15, and IFIT1) was
higher in all regressive CTVTs relative to non-regressive CTVTs,
suggesting activation of the innate immune response (Schneider
et al., 2014). Furthermore, among the most upregulated early
genes were chemotactic cytokines CCL5 and CCL28 (Sozzani
et al., 1996). CCL5 was statistically significantly upregulated in
the regressive CTVTs only; it was one of four early upregulated
genes in the core gene signature of regression, and IPA identified
CCR5 signaling as one of the most significant canonical path-
ways consistently detected across regressing CTVTs. CCL5
recruits dendritic cells, monocytes, and lymphocytes (Turner
et al., 2014), whereas CCL28, expressed by epithelial cells, is a
mucosal-specific cytokine that recruits lymphocytes and eosin-
ophils (Pan et al., 2000).
Keratinocytes can express many chemokines (Sozzani et al.,
1996), therefore we propose that their activation and the
concomitant tissue inflammation result in further enhanced
production of certain chemokines. We propose that, when
CCL5 expression reaches a certain threshold, CTVT regression
becomes likely. This is consistent with the notion that, whereas
low chronic inflammation has a pro-tumor effect, a dramatic
increase in the production of inflammatorymediators by the local
host cells induces a switch from chronic to florid inflammation,
which triggers infiltration by immune cells (Mantovani et al.,
2008). In our case, the initial strong inflammatory response
may be induced by vincristine, which causes the release of
damage-associated molecular patterns from stressed or dying
cells (Kono and Rock, 2008). Because CTVT is an allograft, sub-
stantial, chemokine-mediated recruitment of alloreactive T cells
into the tumor should induce direct recognition of foreign DLA630 Cancer Cell 33, 620–633, April 9, 2018molecules, triggering acute rejection (Kono and Rock, 2008). In
this scenario, low-dose chemotherapy or radiotherapy, far
from causing immunosuppression, would in fact elicit inflamma-
tion and trigger a cascade of events ultimately leading to CTVT
regression.
Thus, our results support the idea of combining low-dose
chemotherapy with immune checkpoint therapy to shift the
balance toward an acute inflammatory response that may trigger
cancer regression in humans (Galluzzi et al., 2015; Mantovani
et al., 2008; Minn and Wherry, 2016; Sharma and Allison,
2015). Cancers that have accumulated many mutations, such
as CTVT (Murchison et al., 2014), may produce many neo-anti-
gens and be more prone to rejection (Gubin et al., 2015).
Our correlative transcriptome and methylome analysis indi-
cated that most changes in gene expression (up or down) were
associated with changes in methylation at particular sites, sug-
gesting that epigenetic mechanisms were at play in eliciting
regression. Indeed, epigenetic regulation of MHC-I expression
has been reported in the Tasmanian devil facial tumor disease
(Siddle et al., 2013). In agreement with previous reports, we
found that methylation changes affecting gene expression
were clustered around the first exon, internal exons, and the
last exon, whereas changes at promoter CpG islands were
less frequent (Hovestadt et al., 2014; Li et al., 2010). It is notable
that the non-regressing CTVT-6 showed a trend toward re-
methylation in the last biopsy, which suggests that the demethy-
lation of upregulated genes needs to be maintained over time for
successful regression. Further work is required to understand
what causes this re-methylation in CTVT-6. Because most upre-
gulated genes appeared to be of host origin, the methylation
analysis points to a critical epigenetic remodeling of host tissue
surrounding the tumor and possibly stroma cells.
Previous reports suggested that CTVT was histiocytic on the
basis of immunohistochemical detection of lysozyme, a1-anti-
trypsin and vimentin in about 30%–50% of the tumor cells
(Marchal et al., 1997; Mozos et al., 1996). However, our tran-
scriptome analysis did not detect expression changes of these
genes at any stage in any of the CTVT samples (although we
note that histamine biogenesis was a prominent canonical
pathway identified by IPA across all regressive CTVTs). The third
biopsy of CTVT-5 demonstrated advanced regression and
almost complete loss of the tumor mass. Because we had serial
biopsies available, we reasoned that genes whose expression
was profoundly downregulated or lost from the second to the
third biopsy in CTVT-5 would provide a ‘‘signature’’ of CTVT.
Skin cancer and cutaneous melanoma were the most highly sig-
nificant networks identified by IPA across all CTVTs on the basis
of the downregulated genes. Analysis of the core signature of
regression also confirmed this result, which was further tested
by independently assessing the relative enrichment of this
gene signature in the NCI-60 human cancer cell line panel origi-
nating from other solid tumors (Pfister et al., 2009). Caution is
required though, because our analysis was not performed on
isolated CTVT cells and our interpretation rests on the assump-
tion that the particular gene signature was mainly due to the loss
of tumor rather than host cells. Despite these limitations, our
result seems plausible because melanocytic and non-melano-
cytic melanoma can form on the genital mucosa (Postow et al.,
2012); hence, as it would be suitably accessible for venereal
transmission, melanoma was previously shown to be transplant-
able across individuals (Scanlon et al., 1965) and it can occasion-
ally regress due to its intrinsic immunogenicity (Papac, 1996).
Furthermore, MHC-II expression can be induced in CTVT and
melanoma (Johnson et al., 2016; Murgia et al., 2006), where it
is associated with an inflammatory signature and a superior
response to anti-PD1 antibody therapy (Johnson et al., 2016).
Melanoma and the Tasmanian devil’s facial tumor are both
neural crest-derived cancers (Murchison et al., 2010; Simoes-
Costa and Bronner, 2013), which raises the intriguing possibility
that some transmissible cancers share a common origin.
In conclusion, our genome-wide scale and systematic analysis
of CTVT regression has provided important new information on
the interplay between chemotherapy, the host tissue, the host
innate and acquired immune system, and the tumor, which
may be applicable in understanding regression of human and
animal cancers.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
anti-5-methylcytosine antibody Diagenode C15200006-100
Biological Samples
CTVT biopsies (see STAR Methods for details) Department of Veterinary Sciences,
University of Messina, Italy and
Veterinary Hospital ’’Dr Halim
Atique’’ - Centro Universita´rio de
Rio Preto (UNIRP), Sa˜o Jose´ do
Rio Preto, Sa˜o Paulo, Brazil
N/A








Proteinase K (ChIP grade) Diagenode C06050002
Critical Commercial Assays
SYBR Green Mix LifeTechnologies/Thermo
Fisher
4309155
DNAse I kit Thermo Fisher AM1906
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems/Thermo
Fisher
4368814
QuantiTect SYBR Green RT-PCR Kit Qiagen 204243
AmpureXT magnetic beads AutoQ Biosciences AQ 60050
Illumina TruSeq RNA Library Prep kit v2 Illumina RS-122-2001
KAPA Stranded mRNA-Seq Kit KAPA Bioscience KK8420
Auto-MeDIP kit Diagenode AF-Auto01-0016
End repair module New England Biolabs E6050L
A-tail module New England Biolabs E6053L
Adapter ligation module New England Biolabs E6056L
MESA BLUE qPCR MasterMix Plus Eurogentec RT-SY2X-03+WOUB
High-fidelity Phusion polymerase (53) New England Biolabs M0530L
dNTP mix New England Biolabs N0447L
Deposited Data
RNAseq for CTVT-5 and CTVT-6 This paper ArrayExpress
E-MTAB-5488
RNAseq for 7xx CTVTs This paper ArrayExpress
E-MTAB-5889
MeD-IP This paper ArrayExpress
E-MTAB-5495
CTVT genome 1 Murchison et al., 2014 European Nucleotide Archive
SAMEA2358413
CTVT genome 2 Murchison et al., 2014 European Nucleotide Archive
SAMEA2358415
Cancer cells transcriptomes ArrayExpress E-GEOD-32474
Oligonucleotides
b-ACTIN Forward: CTCCATCATGAAGTGTGACGTTG Murgia et al., 2006 N/A
b-ACTIN Reverse: CGATGATCTTGATCTTCATTGTGC Murgia et al., 2006 N/A
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
DLA DQA-1 tumour. Forward: GAATTTGATGGCGATGAGTT Murgia et al., 2006 N/A
DLA DQA-1 tumour Reverse: TCAGGATGTTCAAGTTTTGT
TTTAT
Murgia et al., 2006 N/A
DLA DQA-1 common. Forward ACTACGGCATAAATGTCTA
CCAGTC
Murgia et al., 2006 N/A
DLA DQA-1 common Reverse: CAAGTTTCTCAGTGCAC
CCTGT
Murgia et al., 2006 N/A
LINE-MYC Forward: AGGGTTTCCCATCCTTTAACATT Murgia et al., 2006 N/A
LINE-MYC Reverse: AGATAAGAAGCTTTTGCACAGCAA Murgia et al., 2006 N/A
PE.Adapter.1.0:
ACACTCTTTCCCTACACGACGCTCTTCCGATC*T









Methylated qPCR Reverse: CAGTCATAGATGGTCGGT This Paper N/A











[Phos] = 30phosphate group
This Paper N/A
Software and Algorithms
Ingenuity Pathway Analysis (IPA) Qiagen www.qiagen.com/ingenuity
MEV software suite TM4 MeV http://www.tm4.org/mev.html
PicardTools Broad Institute http://broadinstitute.github.io/
picard/
HTSeq-count Anders et al., 2015 http://www-huber.embl.de/
users/anders/HTSeq
TopHat v2.0.13 Trapnell et al., 2009 https://ccb.jhu.edu/software/
tophat/index.shtml
R/BioConductor Gentleman et al., 2004 https://www.bioconductor.org/





DESeq BioConductor library Anders and Huber, 2010 https://bioconductor.org/packages/
release/bioc/html/DESeq.html
DESeq2 BioConductor library Love et al., 2014. http://bioconductor.org/packages/
release/bioc/html/DESeq2.htmlCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Ariberto
Fassati (a.fassati@ucl.ac.uk).Cancer Cell 33, 620–633.e1–e6, April 9, 2018 e2
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Dogs
CTVT biopsies were collected from 9 dogs as detailed below:Sample
Age of
Dog (Years) Sex Breed Location
Year of
Collection Site of Tumor Treatment
CTVT-5 3 M Mixed Messina (Italy) 2009 Penis Vincristine 2 sessions
CTVT-6 4 F Mixed Messina (Italy) 2009 Vestibulum Vincristine 2 sessions
CTVT-17 5 M Mixed Reggio Calabria (Italy) 2009 Penis Vincristine 2 sessions
CTVT-761 5 F Mixed Sa˜o Jose´ do Rio Preto (Brazil) 2012 Vagina Vincristine 6 sessions
CTVT-765 4 F Border-Collie Sa˜o Jose´ do Rio Preto (Brazil) 2012 Vulva Vincristine 7 sessions
CTVT-766 7 F Shih Tzu Sa˜o Jose´ do Rio Preto (Brazil) 2012 Vagina Vincristine 4 sessions
CTVT-772 5 M Mixed Sa˜o Jose´ do Rio Preto (Brazil) 2013 Penis Vincristine 6 sessions
CTVT-774 4 M Mixed Sa˜o Jose´ do Rio Preto (Brazil) 2013 Nose Vincristine 8 sessions
CTVT-775 3 M Border-Collie Sa˜o Jose´ do Rio Preto (Brazil) 2013 Penis Vincristine 7 sessionsBiopsies of CTVT-5 and CTVT-6 were collected from dogs undergoing diagnostic assessment at the Department of Veterinary
Sciences, University of Messina, Italy. Biopsy of CTVT-17 was collected at a kennel in Reggio Calabria, Italy. Biopsies of CTVT-
761, 765, 766, 772, 774 and 775 were collected at the Veterinary Hospital ’’Dr Halim Atique’’ - Centro Universita´rio de Rio Preto
(UNIRP), Sa˜o Jose´ do Rio Preto, Sa˜o Paulo, Brazil. All the procedures on animals treated in Italy were in agreement with welfare
and ethics European directives and were approved by the University of Messina, under protocol number ORME07PFLB. All the
procedures carried out in Brazil were approved by the Animal Research Ethics Committee of the Sa˜o Paulo State University at
Jaboticabal, Sa˜o Paulo, Brazil, under protocol number 24674/2012. All dogs were in good health at the time of the consultation.
Diagnosis of CTVT was done by means of visual inspection of the tumor and evaluation of size, morphology and location, followed
by cytological smears, stained with May-Gr€unwald Giemsa. Apoptotic cells and infiltrating cells were counted manually. Biopsies
were collected by surgical excision, after local infiltrations of lidocaine, frozen in liquid N2 and processed for histology and immuno-
histochemistry. Dogs with confirmed CTVT were treated as follows: CTVT-5 and 6, vincristine sulfate 0.025 mg/Kg iv once and
biopsies were collected at day 0 (before treatment), day 6 and day 14 after treatment; CTVT-17: 0.025 mg/Kg iv vincristine sulfate
once and biopsies collected at day 0, 22, and 48 after treatment; CTVT-761, 765, 766, 772, 774, 775, vincristine sulfate
0.5 mg/m2 iv at weekly intervals and biopsies collected at day 0 (before treatment) and at day 28 after the third dose of vincristine.
METHOD DETAILS
RNAseq
Nucleic acids were extracted from biopsy 1 (pre-therapy), biopsy 2 (day 6 after vincristine) and biopsy 3 (day 14 after vincristine) of
CTVT-5 and CTVT-6; from biopsy 1 (pre-therapy), biopsy 2 (day 22 after vincristine) and biopsy 3 (day 48 after vincristine) of CTVT 17
and from biopsy 1 (pre-therapy) and biopsy 2 (day 28 - after the third dose of vincristine) of CTVT-761, 765, 766, 772, 774, 775 using
Qiagen RNAeasy Blood & Tissue kit following the manufacturer’s instructions.
For CTVT-5, CTVT-6 and CTVT-17, 250 ng of total RNA was prepared for sequencing following the Illumina TruSeq mRNA
(unstranded) protocol with insert size 150-250, multiplexed, and sequenced (V2 High Output kit, 54bp PE) on an Illumina Nextseq
to yield an average of > 15 million reads per sample. Data was de-multiplexed using bcl2fastq v 2.16. Read QC reports were gener-
ated in Illumina Basespace. FASTQ files passing read QC were analyzed on the WTSI genomics cluster using an in house pipeline
(Python/R). Sequencing reads were aligned to Canfam 2.0 reference genome using TopHat v2.0.13 (Trapnell et al., 2009); GTF files
describing genes features were obtained from the Ensembl website (http://www.ensembl.org/info/data/ftp/index.html). Duplicate
reads were then removed using PicardTools (http://broadinstitute.github.io/picard/) /) and read counts per gene generated using
HTSeq-count (http://www-huber.embl.de/users/anders/HTSeq).
For CTVT-761, 765, 766, 772, 774, 775, 1 mg of total RNA was prepared for sequencing following the KAPA Stranded mRNA-Seq
Kit (KAPA Bioscience) protocol with insert size 150-250, multiplexed, and sequenced (V2 High Output kit, 54bp PE) on an Illumina
Nextseq to yield an average of > 10 million reads per sample. RNAseq analysis, data were de-multiplexed using bcl2fastq v 2.17.
Paired end reads were mapped to dog transcriptome reference sequence Canfam 2.0 to make it directly comparable with CTVT
5 and 6. Mapping and generation of read counts per gene were done using Kallisto (Bray et al., 2016).
SNP Mapping
Integrative Genomic Viewer (IGV) was used to visualize mapped reads from CTVT samples and two published CTVTs (Accession
numbers: SAMEA2358413 and SAMEA2358415, downloaded from the ENA) and to manually inspect SNPs (Robinson et al., 2011).e3 Cancer Cell 33, 620–633.e1–e6, April 9, 2018
Quantitative PCR for Genomic DNA
qPCR to detect CTVT and host DNA in CTVT-761, 765, 766, 772, 774 and 775 was performed using an Applied Biosystems 7900HT
Fast Real-Time PCR system in a final volume of 20 mL using SYBR Green Mix (Life Technologies), 20 ng genomic DNA and 5 mM
primers as described in the Key Resources Table. Cycling parameters were 95C, 10min for 1 cycle followed by 95C, 15 s and 60C,
60 s for 40 cycles. Standard curves for LINE-MYC, ACTB,DLADQA-1 tumor andDLADQA-1 commonwere generated using a CTVT
sample. Relative LINE-MYC, ACTB, DLA DQA-1 (tumor) and DLA DQA-1 (common) amplification values were estimated for each
sample using the standard curve. Each qPCR was performed in triplicate. Values were normalized against a standard curve that
was generated for each primer set using CTVT tumour 29T sample as reference, which was previously characterized (Murchison
et al., 2014). This linear standard curve was generated from a range of known relative DNA concentrations of 29T, which could be
used to calibrate each qPCR reaction and calculate the relative amount of DNA input. Relative DNA input for LINE-MYC, DLA
DQA-1 tumor and DLA DQA-1 common was then normalized to ACTB. The relative standard curve was generated according to
the Guide to performing relative quantitation of gene expression using real-time quantitative PCR – Applied Biosystems (Carlsbad,
California, USA).
Methylome
Methylated DNA Immunoprecipitation (MeDIP)-seq was performed using 600 ng genomic DNA from biopsies 1, 2 and 3 of CTVT-5,
CTVT-6 and CTVT-17. DNA was sonicated on a Diagenode Bioruptor (4 x 15 min cycles set to high intensity) to produce a median
fragment length of 180–230 and verified using a 2100 Bioanalyzer with DNA1000 chips (Agilent; p/n 5067-1504). Sample DNA was
prepared for next-generation sequencing as follows:
Firstly, DNA was end repaired: reagents (NEBNext End Repair Enzymemix: 5 ml; NEBNext End Repair Reaction Buffer (10X): 10 ml;
Fragmented DNA: 85 ml) weremixed on ice in a sterile PCR tube and incubated in a thermocycler at 20C for 30min. The reaction was
placed on ice after incubation then spun briefly in a microfuge for 10 s to collect condensate. Next the reaction was purified with
Ampure XP purification beads: end-repaired DNA and 1.83 volumes ofmagnetic beadswere added to a clean 1.5mlmicrocentrifuge
tube, pipette mixed to homogenize and allow DNA to bind to magnetic beads. The mixture was incubated at room temperature for
5 min then placed on amagnetic rack to collect beads/DNA. Supernatant was aspirated off and discarded. Next, 200 ml 70% ethanol
was added to the beads and left for 30 s. Supernatant was aspirated off and discarded. Repeat ethanol wash. Leaving the samples in
magnetic rack, themagnetic rack was placed in oven for 10-15min to evaporate residual ethanol. When beads looked drab, the sam-
ple was taken off the magnetic rack and 37 ml Tris-HCl was added to liberate DNA from beads. The mixture was gently pipette mixed
and incubated for 1min. The samplewas placed back on themagnetic rack to separate the beads. Supernatant was aspirated off and
carried to the dA- Tailing step. Following purification, DNA was dA- tailed: reagents (Klenow Fragment (3’/5’ exo-): 3 ml; NEB Next
dA-tailing Reaction Buffer (10X): 5 ml; water: 5 ml; purified DNA: 37 ml) were mixed on ice in a sterile PCR tube and incubated in a ther-
mal cycler at 37C for 30 min. Following incubation the samples were purified with Ampure XP purification beads and eluted in 25 ml
Tris-HCl for the next step.
Next, paired-end sequencing adapters were added: reagents (Quick T4 DNA Ligase:5 ml; Quick Ligation Reaction Buffer (5x): 10 ml;
paired-end sequencing adapters [PE.Adapter.1.0 and PE.Adapter.2.0]: 10 ml; purified DNA: 25 ml) were mixed on ice in a sterile PCR
tube and incubated in a thermocycler at 18C for 15min. Following incubation the samples were purified with Ampure XP purification
beads and eluted in 25 ml Tris-HCl for the next step.
Following purification of adapter-ligated samples, each sample was spiked with approximately 5x10-7 pmoles methylated/unme-
thylated Enterobacteria phage l DNA derived by PCR of select regions described elsewhere (Taiwo et al., 2012); methylated frag-
ments were obtained by in vitromethylation using SssImethyltransferase. Ten percent sample DNA was reserved as input for quality
control purposes (see below). The remaining DNAwas incubatedwith 150 ng anti-5-methylcytidine at 4C for 15 hrs using automation
and manufacturer reagents and protocols (Diagenode). Following immunoprecipitation, DNA was incubated with 1 mg proteinase K
(Diagenode) at 55C for 15 min then 95C for 15 min. Each sample was subject to quality control using triplicate quantitative PCR
(qPCR) reactions with primers designed to amplify methylated/unmethylated control DNA. Reagents (Eurogentec MESABlue
qPCRmastermix (23): 6.25 ml; Methylated/Unmethylated Forward andReverse primer pairs (10 mM): 0.625 ml; water: 4.375 ml; MeDIP
or input DNA: 1.25 ml) were mixed on ice and incubated on an ABI 7900 qPCRmachine under the following conditions: 95C for 60 s ;
40 cycles of 95C for 30 s and 60C for 60 s then 72C for 5 min. After confirming enrichment of methylated DNA in the immunopre-
cipitated fraction (see Taiwo et al., 2012), DNA was purified using AmpureXP magnetic beads
Following purification, immunoprecipitated DNA samples enriched by adapter-mediated PCR: reagents (water: 2.5 ml; 5x Phusion
buffer: 10 ml; NEB dNTPs: 1.5 ml; PCR_PE_1.0 (10 mM stock): 5 ml; PCR_PE_ 2.0 (10 mM stock): 5 ml; purified DNA: 25 ml; Phusion
Polymerase: 1 ml) were mixed on ice in a sterile PCR tube and incubated under the following conditions: 95C for 30 s; 12 cycles
98C for 20 s, 65C for 30 s, 72C for 30 s, then 72C for 5 min. Following incubation the samples were purified with Ampure XP
purification beads and eluted in 15 ml Tris-HCl. Next, DNA sequencing libraries were size-selected: samples were mixed with
5x loading dye and run out on a 2% TBE agarose gel containing EtBr (1.0 mg/ml), maintaining a minimum of 2 cm between wells.
Electrophoresis was performed at 100 volts for 100 min. Following gel electrophoresis, the gel was transferred to a UV transillumi-
nator with a strip of aluminum foil beneath sample wells. Using a clean scalpel, a 300-350 bp slice was excided and transferred to a
clean 1.5 ml microcentrifuge tube.
Following gel-excision, samples were purified using QIAGEN Gel Extraction kits: 3 volumes of buffer QG were added to 1 volume
gel and vortexed to mix. QG-gel mix was incubated at room temperature until fully dissolved. Next, 10 ml 3 M sodium acetate (pH 5.0)Cancer Cell 33, 620–633.e1–e6, April 9, 2018 e4
was added and mixed. Next, 1 gel volume of isopropanol was added to the sample and mixed by inversion. The sample was trans-
ferred to aMinElute column and centrifuged at 16,000 rpm for 1min. The flow throughwas discarded and 500 ml buffer QGwas added
to the empty sample tube and mixed on a vortex. Next, the 500 ml buffer QG was transferred to MinElute column from the previous
step; left to stand for 1 min and centrifuged at max speed for 1 min. The flow through was discarded. Using a pipette, any residual
buffer QG from inside theMinElute columnwas aspirated and discard before washing. To wash, 750 ml PE wash buffer were added to
the clean-up column. The column was gently inverted several times to thoroughly wash and centrifuged at max for 1 min. The flow
through was discarded and the clean-up column placed back in the same tube. The column was centrifuged for an additional 2 min
and visually inspected to ensure that there was no residual solution in the column. The column reservoir was placed in a clean 1.5 ml
microcentrifuge tube and DNA eluted by adding 10 ml EB directly onto column the membrane, left to stand for 5 min then centrifuged
atmax speed for 1min. 1 ml size selected DNAwas assessed on an Agilent Bioanalyzer using DNAHigh Sensitivity Chips to determine
concentration and molarity.
Samples were sequenced on an IlluminaGAIIx with 36bp paired-end reads. Downstream bioinformatic processing of reads prior to
analysis (i.e., sequence quality control, alignment and filtering) was performed with the MeDUSA pipeline (Wilson et al., 2012). To
construct the methylation boxplots, chromosomal coordinates were determined for the first exon, the first intron, internal exons,
internal introns, and the final exon for each gene, in addition to coordinates corresponding to 2 kb regions up- and downstream
of the first and final exons respectively. These coordinates were used to construct 20 equally spaced bins for each such feature
per gene. Bam files for each sample were converted into individual wig files (Li et al., 2009), from which mean levels of methylation
were calculated for each bin. These values were then concatenated to investigate larger-scale methylation patterns across gene sets
of interest (e.g. non-expressed genes, S/P ‘‘early’’ up-regulated genes, etc.) using in-house Perl scripts and R.
QUANTIFICATION AND STATISTICAL ANALYSIS
Analysis of Gene Expression
For CTVT-5 and CTVT-6, R/BioConductor (Gentleman et al., 2004) was used to import the mapped count data and the DESeq library
(Anders and Huber, 2010) was used to normalize the data, estimate variance, filter low expression genes and then predict differen-
tially expressed genes. Specifically, a filtering step was applied to remove low expression genes whose sum of counts across all
conditions was within the lowest 40%quantile (9886/24660 genes). Counts for the 14774 remaining genes were then fitted to a nega-
tive binomial generalized linear model using a multi-factorial design matrix (tumor stage, dog) and applying a fold-change cut-off
of +/- 10 and a Benjamini-Hochberg adjusted p value cut-off of 0.01.
For the 7xx CTVTs, Tximport was used to import themapped counts data into R and summarize the transcripts-level data into gene
level as described ((Soneson et al., 2015). Counts for 21047 genes were normalized and further analyzed using DESeq2 and the
SARTools packages (Love et al., 2014). Differential gene expression was performed by fitting counts to a negative binomial gener-
alized linear model using a multi-factorial design matrix (design formula of: regression + regression:dog + regression:time).
Heatmaps
The 1016 genes that passed the cut-off (FC>10, adj-p< 0.01) in the old CTVTs and the 1350 genes that passed the same cut-off in the
7xx CTVTs were included in the heatmaps. To generate heatmaps that are consistent across samples, for panel A we calculated log 2
differential expression of the 1016 genes relative to the geometric mean of CTVT-5 B1 and CTVT-6 B1, which corresponds to the
mean of the Log2FC. Genes were sorted by relative differential expression of B3. For panel B, we similarly calculated differential
expression of the 1350 genes relative to the geometric mean of the five B1 samples. Genes were then sorted by the geometric
average relative expression increase in B2s from the three regressing dogs. The raw data used to generate the heatmaps are
provided in Table S2. Heatmaps were generated using heatmap.2 function in the package gplots in R (Gregory R. Warnes, Ben
Bolker, Lodewijk Bonebakker, Robert Gentleman, Wolfgang Huber Andy Liaw, Thomas Lumley, Martin Maechler, Arni Magnusson,
Steffen Moeller, Marc Schwartz and Bill Venables (2016). gplots: Various R Programming Tools for Plotting Data. R package version
3.0.1. https://CRAN.R-project.org/package=gplots).
IPA
The networks and functional analyses were generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN
RedwoodCity, www.qiagen.com/ingenuity). Genes that reached a cut-off of FC>10 and an adj-p< 0.01 were included in the IPA anal-
ysis. Comparative analyses were performed using the specific IPA function, selecting individual IPA outputs and clustering pathways
based on both statistical significance (Fisher’s exact test) and similarity. Diagrams were generated using the Pathdesigner function
from the most highly significant and represented networks in the Diseases and Bio-Functions and Canonical Pathways.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNAseq of CTVT-5 and CTVT-6 reported in this paper is ArrayExpress: E-MTAB-5488.
The accession number for the RNAseq of 7xx CTVTs (761, 765, 766, 772, 774 and 775) reported in this paper is ArrayExpress:
E-MTAB-5889.
The accession number for the MeDIP for CTVT-5, 6 and 17 reported in this paper is ArrayExpress: E-MTAB-5495.e5 Cancer Cell 33, 620–633.e1–e6, April 9, 2018
The accession number for the CTVT genome number 1 reported in (Murchison et al., 2014) is European Nucleotide Archive:
SAMEA2358413. The accession number for CTVT genome number 2 reported in (Murchison et al., 2014) is European Nucleotide
Archive SAMEA2358415.




DESeq BioConductor library: https://bioconductor.org/packages/release/bioc/html/DESeq.html.
DESeq2 BioConductor library: http://bioconductor.org/packages/release/bioc/html/DESeq2.html.Cancer Cell 33, 620–633.e1–e6, April 9, 2018 e6
